Table 5.

Discrepancies between results of analysis of KRAS oncogene point mutations in codon 12 in exhaled breath condensate (EBC), blood and five separate samples of non-small cell lung cancer obtained from the group of 14 patients with clinical diagnosis of lung cancer after complete tumor resection who harbored this mutation in at least one sample

Patient number and diagnosis	Identified KRAS point mutations			Number of discrepancies
	EBC	Blood	Cancer tissue samplesa	EBC versus blood	EBC versus tumor	Blood versus tumor
1. SCC	G12D	(–)	3 G12D, 2 G12V	1	0	1
2. SCC	G12D	(–)	5 G12D	1	0	1
3. SCC	(–)	G12C	3 G12V, 2 G12C	1	1	0
4. SCC	(–)	G12D	5 (–)	1	0	1
5. ADC	G12D	G12D	5 G12D	0	0	0
6. ADC	G12D	G12V	5 G12D	1	0	1
7. ADC	G12D	(–)	3 G12V, 2 G12D	1	0	1
8. ADC	G12D	G12D	5 G12D	0	0	0
9. ADC	G12D	(–)	4 G12D, 1 (–)	1	0	1
10. ADC	G12D	(–)	2 G12D, 3 (–)	1	0	1
11. ADC	(–)	G12D	5 (–)	1	0	1
12. ADSCC	G12D	G12V	1 G12D, 4 (–)	1	0	1
13. LCNEC	G12D	G12D	5 G12D	0	0	0
14. LCNEC	G12D	G12D	3 G12D, 2 (–)	0	0	0
Overall				10	1	9

Five patients who had no detectable KRAS point mutations in any analyzed sample were not shown in the table. The discrepancy between EBC and tumor as well as between blood and tumor was noted when KRAS mutation status (including the wild, not mutated sequence) detected in EBC and blood differed from mutation (or mutations) observed in corresponding set of five cancer tissue samples. The discrepancy between EBC and blood was noted when different mutations or mutation and wild-type sequence were observed

SCC squamous cell carcinoma, ADC adenocarcinoma, ADSCC adenosquamous cell carcinoma, LCNEC large-cell neuroendocrine carcinoma, (–) KRAS mutation not detected

^aNumeral before mutation represents number of cancer tissue samples harboring given point mutation